Trends in incidence, molecular diagnostics, and treatment of patients with breast cancer in Kazakhstan, 2014-2019

Relevance: Globocan reported 4,390 new breast cancer cases and 1,654 deaths from in the Republic of Kazakhstan (RK) 2020. Molecular diagnostics includes determination Hormone Receptor (HR), HER2, Ki-67 status to detect patients
 with HR-positive tumors administer effective treatment.
 Methods: This observational study included a retrospective analysis incidence, molecular diagnostics, treatment regimens women confirmed diagnosis aged 18 years old older, registered RK Electronic Registry Cancer Patients (ERCP) 1 January 2014 till 31 December 2019.
 Results: In period (2014 2019), number annually has doubled. The incidence increased by 46.9%. share locally advanced forms decreased. proportion Luminal type A (HR+/HER2-)
 among newly diagnosed patients ranged 17.9% 30%. Chemotherapy endocrine therapy goserelin, buserelin, leuprorelin, fulvestrant are standard first- second-line treatments for HR+ cancer. Since indications have been expanded, more
 than 50% receive as first-line therapy.
 Conclusion: Breast growth decrease could be attributed coverage eligible 40 70 mammographic screening. Although international guidelines support administration hormone or without targeted HR-positive, HER2-metastatic cancer, upfront use chemotherapy remains common even absence visceral crisis. CDK4/6 inhibitor palbociclib combination become routinely available since 2019